Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subacute Cutaneous Lupus Erythematosus Clear all
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
61
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 2:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
Interventions
Skin biopsy, Blood collection, Urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced May 22, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced May 22, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Cutaneous Lupus, Lupus
Interventions
AMG 557, AMG 557 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced May 22, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 2:48 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced May 22, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Troy, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
M5049 low dose, M5049 medium dose, M5049 high dose, Placebo
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 76 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 22, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Cooper City, Florida • Charlotte, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced May 22, 2026, 2:48 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Combination Product · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Covina, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 2:48 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lupus
Interventions
BMS-986326, Placebo for BMS-986326
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
San Diego, California • Clearwater, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 22, 2026, 2:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
Interventions
Skin Taping, Blood Sampling, Skin Biopsy
Procedure
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced May 22, 2026, 2:48 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
CC-11050, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced May 22, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Upland, California • DeBary, Florida • Pembroke Pines, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced May 22, 2026, 2:48 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 2:48 AM EDT
Enrolling by invitation Phase 3 Interventional
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 2:48 AM EDT